1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

  • January 2016
  • 164 pages
  • BCC Research
Report ID: 3479639


Table of Contents

This BCC Research report provides an up-to-date analysis of recent developments and current trends in the global erythropoietin drug market. Includes forecast through 2020.

Use this report to:

Gain information about the various types applications of erythropoietin stimulating agents.
Analyze current trends within the industry, major industry challenges, and the regional dynamics of the global erythropoietin drug market.
Quantify the projected impact of both internal and external forces affecting the global erythropoietin drug market today and over the next several years.
Analyze detailed profiles of major vendors in the erythropoietin drug industry globally.


The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.
The Epoetin-alfa drug market is the largest segment and should reach approximately $3.3 billion in 2015 and nearly $2.1 billion by 2020, a CAGR of -8.4%.
The Epoetin-omega drug market is expected to increase from nearly $371.8 million in 2015 to nearly $1.1 billion in 2020, a CAGR of 23.3%.


The global market for erythropoietin drug can be broadly classified into two segments:
biologics and biosimilars.
The major types of biologic erythropoietin drugs based on different biological properties are epoetin-alfa, epoetin-beta, darbepoetin-alfa and epoetin-theta.
The major types of biosimilar erythropoietin drug based on the different biological properties are epoetin-zeta, epoetin-omega, epoetin-lambda and epoetin-delta.
The global erythropoietin biologics drug market has been growing in terms of value from the past 15 years in pace with the increasing prevalence of chronic kidney diseases throughout the world, however the market is expected to see decline in the forecast period due to expiry of major patented drugs in the U.S. and European markets; and due to the entrant of many biosimilar erythropoietin drug in the European market since 2008 which are approximately 20% to 30% cheaper compared to patented drug.

The global erythropoietin biosimilars drug market has been growing rapidly in the last decade years, primarily due to the patent expiry of major erythropoietin biologic drug in European market and demand for cheaper priced erythropoietin drugs in the Asia-Pacific, South America, Middle-east and African market. The study covered in this
report has been conducted to analyze and quantify the emerging market opportunities for erythropoietin drug, as well as to highlight the key current research efforts that are driving erythropoietin drug into new applications. In addition, major players of the erythropoietin drug, along with their upcoming and anticipated erythropoietin-related
products are analyzed to demonstrate how these advances might impact global erythropoietin drug market.

The application of erythropoietin drug is divided broadly into three types: chronic kidney diseases; oncology diseases; and other applications such as treatment of anemia in HIV patients. The key drivers for the erythropoietin drug market are increasing case of chronic disease and increasing prevalence of cancer.
Amgen Inc., Hoffmann-La Roche and Johnson & Johnson are some of the key players of biologics erythropoietin drug market. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer Inc.), 3SBio, BioSidus and Teva Pharmaceutical Industries Ltd. are some of the major players of biosimilar erythropoietin drugs market.
The market for erythropoietin in Asia-Pacific and South America is expected to grow at the fastest rate compared to other global markets, which are expected to decline. The entrant of erythropoietin biosimilars drugs in Europe and the U.S. will create a huge impact during the forecast period, resulting in a decline in the global erythropoietin drug market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017
  • by MP Advisors

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.